San Antonio, TX

ICON

Obesity

Overweight

COVID-19

Pegfilgrastim

Lubiprostone

Atorvastatin

Neulasta

NNC0638-0355

NNC0519-0130

CHS-1701

Coherus BioSciences

Novo Nordisk

AbbVie

Gannex Pharma

KBio Inc

Sucampo

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

ICON | San Antonio, TX

Site insights

Work at this site?

Active trials

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

Trial sponsors